In Vitro Hepatic Microsomal Metabolic Stability Assay with LC-MS/MS Quantification of Intrinsic Clearance

Each compound is incubated at 1 µM with 0.5 mg/mL microsomal protein, sampled at 7 time points (0, 5, 10, 15, 30, 45, 60 min) in technical triplicate, across 2-3 independent microsome-incubation runs. A minus-NADPH control series (chemical-stability control) and reference compounds spanning low (e.g. warfarin), medium, and high (e.g. verapamil, midazolam) clearance are run in parallel on every plate. Reactions are temperature-equilibrated at 37 C and quenched into cold acetonitrile with internal standard.

BSL-1. Human liver microsomes are human-derived biological material — handle with universal precautions, nitrile gloves, and lab coat; treat as potentially infectious and dispose as biohazard. Acetonitrile and methanol are flammable and toxic — use in a fume hood, away from ignition sources, and dispose as flammable organic waste. Formic acid is corrosive. LC-MS solvent waste goes to compatible organic-waste streams. Wear safety glasses; manage compressed gases (nitrogen) for the MS per facility rules.

Minus-NADPH control: identical incubation without the NADPH cofactor distinguishes enzymatic metabolism from chemical/physical loss (a stable parent here confirms CYP-dependence). Reference controls: verapamil/midazolam (high clearance) and warfarin (low clearance) verify microsome activity and assay dynamic range each run. Zero-time control defines 100% parent (must be quenched before NADPH addition). A no-microsome incubation controls for non-enzymatic binding/instability. Internal standard normalizes for injection and matrix variability.

Plotting ln(% parent remaining) vs time gives a straight line for first-order kinetics over the depletion phase, with R2 >= 0.95. High-clearance references (verapamil/midazolam) deplete rapidly (t1/2 typically < 15 min); warfarin shows minimal depletion (< 20% at 60 min). Minus-NADPH samples remain flat (> 80% remaining), confirming enzymatic metabolism. CLint typically reported in µL/min/mg protein and scaled to predicted hepatic clearance.

• Pooled human liver microsomes (mixed gender), 20 mg/mL stock, stored at -80 C
• Potassium phosphate buffer, 100 mM, pH 7.4
• NADPH-regenerating system (NADP+, glucose-6-phosphate, G6PDH, MgCl2) or 1 mM NADPH directly
• Test compounds, 10 mM in DMSO (final DMSO <= 0.1%, acetonitrile <= 1%)
• Reference controls: verapamil, midazolam, warfarin (10 mM stocks)
• Quench solution: ice-cold acetonitrile containing analytical internal standard (e.g. tolbutamide, 50 nM)
• LC-MS/MS mobile phases: A = 0.1% formic acid in water, B = 0.1% formic acid in acetonitrile
• 96-well incubation and quench plates
• C18 analytical column

To quantify the rate of Phase I (cytochrome P450-mediated) metabolism of test compounds using pooled human liver microsomes and an NADPH-regenerating system, by monitoring parent-compound disappearance via LC-MS/MS. This protocol yields the in vitro half-life (t1/2), intrinsic clearance (CLint), and scaled predicted hepatic clearance, enabling early triage of compounds with high metabolic liability during lead optimization.

1. Thaw microsomes on ice; prepare a master mix of microsomes (0.5 mg/mL final) + compound (1 µM final) in phosphate buffer, minus NADPH.
2. Pre-warm the master mix and the NADPH-regenerating system separately at 37 C for 5 min.
3. Initiate reaction by adding NADPH system to the master mix (total volume e.g. 300 µL per condition); start timer.
4. At each time point (0, 5, 10, 15, 30, 45, 60 min) remove a 30 µL aliquot.
5. Immediately quench each aliquot into 90 µL ice-cold acetonitrile + internal standard to stop metabolism.
6. For the minus-NADPH control, run the identical time course with buffer replacing the NADPH system.
7. Centrifuge quenched plates at 3,500 x g for 15 min at 4 C to pellet precipitated protein.
8. Transfer supernatant to a clean plate; dilute with water if needed for chromatography.
9. Quantify parent compound by LC-MS/MS in MRM mode, normalizing peak area to the internal standard.

Independent variable: incubation time (7 time points). Dependent variable: parent compound peak-area ratio (analyte/internal standard), expressed as % remaining. Controlled variables: microsomal protein concentration (0.5 mg/mL), substrate concentration (1 µM), buffer pH and ionic strength, incubation temperature (37 C), NADPH concentration, organic solvent content, and LC-MS/MS MRM transitions and injection volume.

Compounds that are good substrates for hepatic CYP enzymes will undergo NADPH-dependent depletion, producing a first-order (log-linear) decline in parent concentration over time. We hypothesize that metabolically labile compounds show short in vitro t1/2 and high CLint, whereas metabolically stable compounds show minimal depletion (< 20% loss at 60 min) and require a longer time course or higher microsomal protein to resolve clearance.

Compute % parent remaining at each time point from analyte/IS peak-area ratio relative to t=0. Fit ln(% remaining) vs time by linear regression; the slope (-k) gives the elimination rate constant. Calculate t1/2 = 0.693/k. Compute CLint (µL/min/mg) = k x (incubation volume / microsomal protein amount). Scale to predicted hepatic CLint and apply the well-stirred liver model with standard scaling factors (microsomal protein per gram liver, liver weight, hepatic blood flow) to estimate CLh. Use the analyst's chromatography software for MRM integration.

1. No depletion of a known labile compound: NADPH system inactive or omitted — prepare fresh NADPH and confirm with verapamil. 2. Non-linear ln plot: incubation outside first-order range or substrate too high — keep substrate <= 1 µM and microsomes <= 1 mg/mL. 3. Loss in minus-NADPH control: non-enzymatic instability or non-specific binding — reduce protein, check chemical stability separately. 4. Poor LC-MS reproducibility: matrix effects or carryover — use internal standard normalization, add blanks, and optimize gradient. 5. Excessive protein precipitate carryover: insufficient quench or centrifugation — use >= 3x acetonitrile and spin at 3,500 x g, 15 min, 4 C.

Report t1/2 and CLint as mean +/- SD across replicate incubations (n=2-3). Use only time points within the linear (first-order) depletion window for regression; exclude compounds with < 20% total turnover from CLint estimation (report as 'low clearance, below quantitation limit'). Compare CLint across compounds by one-way ANOVA with Tukey's correction at alpha = 0.05 where biological replication permits. Assay acceptance requires reference compounds within historical 2-fold ranges.